ORGO Q4 2021 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$355M

Q4 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$129M+20.4% YoY

Gross Profit

$96M74.6% margin

Operating Income

$20M15.9% margin

Net Income

$52M40.2% margin

EPS (Diluted)

$0.39

QoQ Revenue Growth

+13.0%

Cash Flow

Operating Cash Flow

$18M

Free Cash Flow

$13M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$443M

Total Liabilities

$202M

Stockholders' Equity

$241M

Cash & Equivalents

$114M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$129M	$107M	+20.4%
Gross Profit	$96M	$81M	+18.1%
Operating Income	$20M	$22M	-6.1%
Net Income	$52M	$18M	+179.5%

Revenue Segments

Advanced Wound care

$121M94%

Surgical and Sports Medicine

$7M6%